Skip to main content
. 2022 Apr 28;13:893137. doi: 10.3389/fimmu.2022.893137

Figure 7.

Figure 7

The effect of HSP90 inhibition on the NK cell degranulation response, granzyme B and IFNγ production in lymphoma patients. NK cell degranulation, as measured by CD107a surface expression, and granzyme B/IFNγ production in PB (n=4) of lymphoma patients and healthy controls (n=5) and BM (n=3) of lymphoma patients. PBMC (A) and BM MNC (B) were pre-treated with geldanamycin (0.1µM) or DMSO in the presence of IL-2 (100IU/ml) and IL-15 (10 ng/ml) and stimulated with anti-NKp46/anti-CD2. (C) Representative flow cytometry plots of CD107a+/Granzyme B+ double positive NK cells on the left and the frequency of CD107a single positive (SP) and Granzyme B SP NK cells in response to IL-2/IL-15 and anti-NKp46/anti-CD2 stimulation. (D) Representative flow cytometry plots of CD107a+ IFNγ+ NK cells on the left and the frequency of CD107a+IFNγ+ NK cells in response to IL-2/IL-15 and anti-NKp46/anti-CD2 stimulation. Graphs show mean ± SEM. ns, not significant, *p<0.05, **p< 0.01. GA, Geldanamycin; BCL, B-cell lymphoma.